According to a recent LinkedIn post from Okami Medical, interventional radiologist Dr. Ahmad Hashmi recently used the company’s LOBO-9 device in an 86-year-old patient with splenic trauma. The post indicates that the procedure achieved rapid vessel occlusion via a guide catheter without requiring additional embolic devices.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights LOBO as a tool aimed at improving speed and procedural efficiency in embolization. For investors, the clinical use case suggests growing real-world adoption in trauma settings, which could support revenue growth, strengthen Okami Medical’s positioning in the interventional radiology market, and enhance its competitive profile in embolization-focused MedTech solutions.